Peptides DB
Research-centric peptide and protocol reference hub
Study 38 of 38Vosoritide literatureClinical and experimental rheumatology · Observational2023

Sex-specific risk profiles of drug-associated joint stiffness and deformity: a FAERS-based pharmacovigilance study with Canadian Vigilance Adverse Reaction Database validation.

This study identifies vosoritide as having a notable association with joint deformity, with a risk profile that varies by sex. Clinicians should be aware of these potential adverse reactions when prescribing.

Read at Clinical and experimental rheumatologyAdd to compare

Where it sits

this study against the rest of the vosoritide corpus
1
Preclinical
23
Observational · this one
0
Open-label
6
Randomised
8
Reviews

Summary and findings

This study examined drug-associated joint stiffness and deformity using adverse event reports from the FDA Adverse Event Reporting System. It identified 23,763 reports of joint stiffness and 1,414 reports of joint deformity, with vosoritide showing a risk of 125.78. The findings highlight sex-specific differences in adverse drug reactions.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
vosoritide, ROR=125.782023

Abstract

The authors’ words, as Clinical and experimental rheumatology supplied them

<h4>Objectives</h4>Joint stiffness and joint deformity are debilitating musculoskeletal adverse drug reactions, yet their risk profiles and sex-specific differences remain poorly characterised. This study aimed to identify drug-associated safety signals and sex disparities using real-world pharmacovigilance data.<h4>Methods</h4>Adverse event reports from the FDA Adverse Event Reporting System (FAERS; Q1 2004-Q2 2025) were analysed. Drug names and events were standardised using RxNorm and MedDRA 27.1. Disproportionality analyses (ROR) with false discovery rate correction were performed overall and by sex. External validation was conducted using the Canadian Vigilance Adverse Reaction Database (CVARDD). Weibull modelling assessed time-to-onset patterns.<h4>Results</h4>We identified 23,763 joint stiffness and 1,414 joint deformity reports, predominantly in females. For joint stiffness, frequently implicated drugs included methotrexate, dupilumab, and fluoroquinolones, alongside 20 newly detected signals (e.g. contrast media, ROR=217.1; gadopentetic acid, ROR=26.14). For joint deformity, alendronic acid, valproic acid, and somatropin showed strong associations, and nine novel signals were identified (e.g. vosoritide, ROR=125.78). Sex-stratified analyses revealed distinct risk profiles: females were more susceptible to bone metabolism and endocrine drugs, whereas males exhibited higher risks with enzyme replacement therapies. Time-to-onset analyses showed an early-failure pattern, with median onset as early as 63 days for methotrexate. Major signals were confirmed by the CVARDD.<h4>Conclusions</h4>This study provides comprehensive real-world evidence of sex-specific differences in drug-associated joint stiffness and deformity, identifies 29 previously unreported signals, and highlights the early-onset nature of these adverse events. These findings support targeted monitoring and personalised risk management, and may inform future updates to drug safety labelling.

Background

This paper addresses the risk profiles of drug-associated joint stiffness and deformity, which are significant adverse drug reactions. Prior research has indicated that these reactions can vary by sex, but detailed characterizations were lacking. Understanding these differences is crucial for improving patient safety and informing clinical practice.

Methods

The study conducted a pharmacovigilance analysis using adverse event reports from the FDA Adverse Event Reporting System (FAERS) from Q1 2004 to Q2 2025. Disproportionality analyses were performed using the reporting odds ratio (ROR) method, and external validation was conducted with the Canadian Vigilance Adverse Reaction Database. Time-to-onset patterns were assessed using Weibull modeling.

Results

A total of 23,763 reports of joint stiffness and 1,414 reports of joint deformity were identified. Vosoritide was associated with joint deformity, showing an ROR of 125.78. The analysis revealed that females were more affected by bone metabolism and endocrine drugs, while males had higher risks with enzyme replacement therapies. The median onset for methotrexate-related joint stiffness was reported as 63 days.

Interpretation

The findings suggest that there are significant sex-specific differences in the risk of joint stiffness and deformity associated with various drugs, including vosoritide. While the ROR for vosoritide is statistically significant, the clinical significance remains uncertain without further context on the severity and prevalence of these adverse events. The study is limited by the nature of adverse event reporting, which may not capture the full scope of drug safety.

Key findings

  • 23,763 joint stiffness reports identified, predominantly in females.
  • 1,414 joint deformity reports identified, with vosoritide showing ROR=125.78.
  • Median onset for methotrexate-related joint stiffness was 63 days.
  • 20 newly detected signals for joint stiffness and 9 for joint deformity were identified.

Limitations

  • Reliance on adverse event reporting data.
  • Potential underreporting and bias in data.
  • Observational study design does not establish causation.
  • Single-site validation may limit generalizability.

Elsewhere in the Vosoritide corpus

AVosoritide Treatment in Children with Hypochondroplasia: Three-Year Results from a Phase 2 Extension Trial.Genetics in medicine : official journal of the American College of Medical Genetics · 2026 · n=13 · Mean height SDS increased by 0.72 SD from Day 1 to Year 3, reaching -2.64±0.79 SD on the CDC growth charts.HumanAVosoritide Treatment in Children with Hypochondroplasia: Three-Year Results from a Phase 2 Extension Trial.Genetics in medicine : official journal of the American College of Medical Genetics · 2026 · Mean height SDS increased by 0.72 SD from Day 1 to Year 3, reaching -2.64±0.79 SD.HumanBAchondroplasia: From bone to bench to bedside an integrated review of medical and surgical management strategies.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2026 · Not reported in abstract.reviewBReal-world evidence of vosoritide treatment in children under 2 years of age with achondroplasia in Colombia: a cases seriesbiorxiv-preprint · 2026 · Mean age at last evaluation was 25.2 months (range 17–30 months).HumanBEvaluation of sleep-related breathing disorders and polysomnography findings in pediatric patients with achondroplasia.European journal of pediatrics · 2026 · n=49 · Median total AHI was 3.2 events/hour in children receiving vosoritide and 6.9 in those not receiving treatment (p=0.105).HumanBRetinal Structural and Microvascular Findings During Novel NPR-B-Targeted Vosoritide Therapy in Children with Achondroplasia.Journal of clinical medicine · 2023 · n=12 · p < 0.05 for nominal increases in RNFL thickness.Human